Spyre Therapeutics

IPO

Engineering for new heights in the treatment of IBD and beyond

Public · Waltham, United States · Founded 2023 · $180.0M raised

Employees
51–200
Founded
2023
Business Model
B2B
Website
spyre.com
Total Funding
$180.0M
Last Round
$180.0M Private EquityDec 2023
Rounds
1
Type
Public

About

Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation, long-acting antibodies engineered as monotherapies and combination therapies for inflammatory bowel disease and rheumatic conditions. The company combines best-in-class antibody engineering with rational therapeutic combinations and precision immunology to maximize efficacy, safety, and convenience for patients. Spyre trades on Nasdaq under ticker SYRE, formerly known as Aeglea BioTherapeutics before its 2023 transformation.

Summary

Spyre Therapeutics is a Biotech company based in Waltham, United States, founded in 2023. It has raised $180.0M in total across 1 round, most recently a $180.0M Private Equity round in Dec 2023.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketApr 2026

Sign up to see all 3 rounds

Private Equity through Secondary Market — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Spyre Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/spyre-therapeutics"><img src="https://indexed.vc/api/badge/company/spyre-therapeutics" alt="Spyre Therapeutics on Indexed.vc" width="260" height="76" /></a>